Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving the German biotech trying to find a silver lining in the drug’s potential ...
OcuTerra Therapeutics’ investigational eye drops failed to improve disease severity or progression in a phase 2 diabetic retinopathy trial, prompting the Boston-based biotech to look at strategic ...
Helldivers 2 can be an incredibly entertaining title, but it isn’t without its flaws. Case in point: you likely found this guide because you were hit with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results